Juvenile dermatomyositis novel treatment approaches and outcomesVarnier, Giulia C.a; Pilkington, Clarissa A.a; Wedderburn, Lucy R.a,b,cCurrent Opinion in Rheumatology: November 2018 - Volume 30 - Issue 6 - p 650–654 doi: 10.1097/BOR.0000000000000538 MYOSITIS AND MYOPATHIES: Edited by Andrea Doria and Anna Ghirardello Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The aim of this article is to provide a summary of the recent therapeutic advances and the latest research on outcome measures for juvenile dermatomyositis (JDM). Recent findings Several new international studies have developed consensus-based guidelines on diagnosis, outcome measures and treatment of JDM to standardize and improve patient care. Myositis-specific antibodies together with muscle biopsy histopathology may help the clinician to predict disease outcome. A newly developed MRI-based scoring system has been developed to standardize the use of MRI in assessing disease activity in JDM. New data regarding the efficacy and safety of rituximab, especially for skin disease, and cyclophosphamide in JDM support the use of these medications for severe refractory cases. Summary International network studies, new biomarkers and outcome measures have led to significant progress in understanding and managing the rare inflammatory myositis conditions such as JDM. aPaediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Foundation Trust bInfection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health cNIHR GOSH Biomedical Research Centre (BRC), London, UK Correspondence to Giulia C. Varnier, MD, Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK. Tel: +44 020 7405 9200ext7887; e-mail: email@example.com Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.